Prothena Corp Public Ltd Co (NASDAQ: PRTA)

Prothena Corp Public Ltd Co, also known as PRTA, is a biotechnology company that specializes in protein dysregulation. The company was established in 2012 and its ordinary shares began trading on the Nasdaq Global Market under the symbol 'PRTA' on December 21, 2012. Prothena's main business activities involve the discovery, development, and commercialization of novel therapies for the treatment of neurodegenerative and rare peripheral amyloid diseases.

Prothena's pipeline includes five therapeutic antibody programs currently in clinical development. These include birtamimab for the potential treatment of AL amyloidosis, prasinezumab in collaboration with Roche for the potential treatment of Parkinson's disease and other related synucleinopathies, NNC6019, which is being developed by Novo Nordisk, for the potential treatment of ATTR amyloidosis, PRX012 for the potential treatment of Alzheimer's disease, and BMS-986446, in collaboration with BMS, for the potential treatment of Alzheimer's disease.

The company generates revenue through its wholly-owned programs, including birtamimab for the potential treatment of AL amyloidosis, and its partnered programs, including prasinezumab for the potential treatment of Parkinson's disease and other related synucleinopathies, and programs that target tau, TDP-43, and an undisclosed target for the potential treatment of Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases, respectively.

Prothena's strategy is to focus on diseases that lack effective therapies, pursue strategic business development opportunities and collaborations, and leverage external resources. The company has a robust discovery engine that generates new targets and compounds that have the potential to treat unmet medical needs. The company also has a diverse pipeline that includes antibody, small molecule, and vaccine approaches.

One of Prothena's key products is birtamimab, an investigational humanized antibody that targets toxic misfolded light chain that causes organ dysfunction and failure in patients with AL amyloidosis. The company has demonstrated a significant survival benefit in patients with Mayo Stage IV AL amyloidosis, with a statistically significant survival benefit of 74 percent observed for those treated with birtamimab plus standard of care (SOC) versus 49 percent in patients on placebo plus SOC at 9 months.

Another important product in Prothena's pipeline is prasinezumab, an investigational humanized monoclonal antibody that targets alpha-synuclein, a protein found in neurons that can aggregate and spread from cell to cell, resulting in the neuronal dysfunction and loss that causes Parkinson's disease and other synucleinopathies. Prasinezumab is the focus of the company's worldwide collaboration with Roche.

Prothena has entered into several collaborations and license agreements with other companies, including Roche, Novo Nordisk, and Bristol Myers Squibb (BMS). These collaborations and license agreements have provided the company with significant upfront payments, milestone payments, and potential royalties. The company has also received funding from these collaborations and license agreements to support the development of its pipeline.